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ABSTRACT
The PI3K/Akt/mTOR signaling cascade is a key regulatory pathway 
controlling cell growth and survival, and its dysregulation is a reported feature of 
B-precursor acute lymphoblastic leukemia (B-pre ALL). 
Torin-2 is a novel, second-generation ATP-competitive inhibitor that is potent 
and selective for mTOR with a superior pharmacokinetic profile to previous inhibitors. 
It has been shown that Torin-2 displayed dramatic antiproliferative activity across a 
panel of cancer cell lines. 
To investigate if Torin-2 could represent a new option for the treatment of B-pre 
ALL, we tested its activity on a panel of B-pre ALL cell lines. In all of them Torin-2 
showed a powerful cytotoxic activity, inhibiting the growth of each cell line in a dose-
dependent manner, with an IC50 in the nanomolar range. Torin-2 caused both apoptosis 
and autophagy, induced cell cycle arrest in G0/G1 phase and affected both mTORC1 
and mTORC2 activities as assessed by their specific substrate dephosphorylation. 
Torin-2 alone suppressed feedback activation of PI3K/Akt, whereas the mTORC1 
inhibitor RAD001 required the addition of the Akt inhibitor MK-2206 to achieve the 
same effect. These pharmacological strategies targeting PI3K/Akt/mTOR at different 
points of the signaling pathway cascade might represent a new promising therapeutic 
strategy for treatment of B-pre ALL patients. 
INTRODUCTION 
mTOR is a highly conserved and widely 
expressed serine/threonine kinase, that is a member of 
the phosphatidylinositol-3 kinase–like kinase (PIKK) 
family, which also includes other protein kinases that 
regulate DNA damage responses, such as ATM (ataxia 
telangiectasia-mutated kinase) and ATR (ATM [ataxia 
telangiectasia-mutated]- and Rad3-related kinase) [1, 2]. 
mTOR plays a pivotal role in the PI3K/Akt/mTOR 
signaling pathway, which senses growth factor and serves 
as a central regulator of fundamental cellular processes 
such as cell growth/apoptosis, autophagy, translation, and 
metabolism [3, 4]. Activation of PI3K recruits cellular 
protein kinases that in turn activate downstream kinases, 
including the serine/threonine kinase Akt. Phosphorylation 
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of Akt activates the mTOR complex 1 (mTORC1) and 
induces subsequent phosphorylation of S6K, and of 
the eukaryotic translation initiation factor 4E-binding 
protein 1 (4E-BP1). The activation of mTORC1 results in 
increased translation and protein synthesis [5]. A second 
complex of mTOR, known as mTORC2, has been more 
recently described and appears to act as a feedback loop 
via Akt [6].
Gene deletions/mutations and functional impairment 
of many proteins involved in this signaling pathway lead 
to a deregulation that results in different human cancers, 
including hematological malignancies. Furthermore 
hyperactivation of this pathway through loss of negative 
regulators, such as PTEN, or mutational activation of 
receptor tyrosine kinases upstream of phosphoinositide 
3-kinase (PI3K) is a frequent occurrence in leukemia 
patients, where it negatively influences response to 
therapeutic treatments [7]. Acute lymphoblastic leukemia 
(ALL) is the most common pediatric malignancy and 
B-precursor acute lymphoblastic leukemia (B-pre ALL) 
is the most frequent pediatric ALL subtype, characterized 
by an aggressive neoplastic disorder of early lymphoid 
precursor cells [8, 9]. The treatment protocol for B-pre 
ALL includes an intense chemotherapy regimen with cure 
rates of 15–80% [10, 11].
In B-pre ALL many research efforts are currently 
devoted to the development of targeted therapies to limit 
side effects of chemotherapy and to increase treatment 
efficacy for poor prognosis patients, i.e. poor outcome 
following relapse [12, 13]. PI3K/Akt/mTOR pathway 
activation is a frequent feature in B-pre ALL [12] and 
therefore this pathway is an attractive target to efficiently 
treat this disease. A new class of ATP-competitive 
mTOR inhibitors, such as Torin-2, have been shown to 
potently target mTORC1 and mTORC2 [14]. Torin-2 is 
also a potent inhibitor of ATR, ATM, and DNA-PK. This 
compound exhibits an anti-tumour activity more broad-
based and profound compared to the rapalogs that do not 
fully inhibit mTORC1 and are unable to inhibit mTORC2 
[15]. 
We therefore hypothesized that dual inhibition 
of mTORC1 and mTORC2 by Torin-2 would provide a 
superior outcome in B-pre ALL as compared to inhibition 
of mTORC1 obtained with RAD001 [16]. We tested the 
cytotoxic activity of Torin-2 and its capability to prevent 
Akt reactivation after mTORC1 and mTORC2 inhibition. 
Furthermore we explored if dual targeting of mTORC1 
and Akt, with RAD001 and MK-2206 respectively, might 
achieve results similar to those obtained with Torin-2 
alone.
Torin-2 displayed a powerful cytotoxic activity 
with an IC50 in the nanomolar range, induced G0/G1 
phase cell cycle arrest, modulated the PI3K/Akt/mTOR 
pathway and caused apoptosis and autophagy in a dose-
dependent manner. Interestingly, feedback activation 
of PI3K/Akt was suppressed by Torin-2 alone, whereas 
RAD001 required the addition of MK-2206 to achieve 
the same efficacy. These findings indicates that mTORC1 
and mTORC2 inhibition could be an attractive strategy to 
develop innovative therapeutic protocols for the treatment 
of B-pre ALL leukemia patients and to prevent Akt 
reactivation after mTORC1 targeting.
RESULTS
PI3K/Akt/mTOR pathway activation status in 
B-pre ALL cell lines 
We first analyzed by Western blot the baseline 
expression of key components of the PI3K/Akt/mTOR 
pathway and their phosphorylation status in a panel 
of human B-pre ALL cell lines (NALM-6, SEM, REH, 
RS4;11, BV-173, SUP-B15, TOM-1). Three of these 
cell lines, BV-173, SUP-B15 and TOM-1 are Ph+, since 
they harbour the Bcr-Abl fusion protein. Despite some 
heterogeneity, all the B-pre ALL cell lines displayed 
phosphorylation at the Ser 2448 and Ser 2481 (readout for 
mTORC1 and mTORC2, respectively) residues of mTOR 
and at the Ser 473 residue of Akt, which are indicative of 
the constitutive activation of this signaling pathway (Fig. 
1).
We further explored the basal condition of 
downstream targets of both kinases. In agreement with 
the hyperactivated status of mTORC1, the ribosomal 
protein S6 and the eukaryotic translation initiation factor 
4E-binding protein 1 (4E-BP1) were phosphorylated at Ser 
235/236 and Thr 37/46 respectively (Fig. 1). A readout for 
mTORC2 activity is represented by the phosphorylation 
at the Ser 473 site of Akt. Hyperactivation of Akt resulted 
in the phosphorylation at the Thr 32 site of Forkhead box 
O3A (FoxO3A) (Fig. 1).
Torin-2 induces cytotoxicity, blocks cell cycle 
progression at the G0/G1 phase and induces 
autophagy
To determine whether Torin-2 could affect viability 
of B-pre ALL cell lines, cells were incubated in the 
presence of increasing concentrations of Torin-2 for 48h 
and then analyzed by MTT assays. All cell lines resulted 
sensitive to the drug, in a concentration-dependent 
fashion, with the IC50 value that ranged between 0.07 
µM and 0.19 µM (Fig. 2A). Given the importance of the 
PI3K/Akt/mTOR signaling pathway in the regulation 
of cell proliferation, the effects of Torin-2 on cell cycle 
progression were also investigated. SEM and BV-173 
cell lines were treated with increasing concentrations 
of Torin-2 for 24h, then cells were harvested, fixed and 
stained with Propidium Iodide (PI) and analyzed with the 
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MuseTM Cell Analyzer. The assay showed in both cell lines 
a concentration-dependent increase of G0/G1 phase of cell 
cycle and a simultaneous decrease in the S phase (Fig. 
2B).
Autophagy can be a form of programmed cell death, 
but is also involved in protective mechanisms against 
apoptosis [17, 18]. To evaluate whether the treatment 
with Torin-2 could lead to autophagy, we detected the 
expression of LC3A/B I (non lipidated) and LC3A/B II 
(lipidated) by Western blot in BV-173, SEM and NALM-
6 cells treated with increasing concentrations of Torin-2. 
The expression levels of LC3A/B II gradually increased in 
the three cell lines in a dose-dependent manner (Fig. 2C). 
To verify whether autophagy was either a cell 
survival or a cell death mechanism, we used the autophagy 
inhibitor 3-MA (3-Methyladenine), which blocks an 
early stage of autophagy by inhibiting the class III 
phosphoinositide 3-kinase (PI3K) [19]. 3-MA alone did 
not affect cell growth, even at the concentration of 10 µM 
(cell viability was comparable to untreated cells), but cells 
treated with 3-MA become significantly more resistant 
to Torin-2 cytotoxic effect (Fig. 2D, upper panel). We 
also employed Bafilomycin A1, another well established 
autophagy inhibitor that inhibits vacuolar ATPase 
(V-ATPase) and promotes the accumulation of autophagic 
vacuoles [20]. As shown in the lower panel of Fig. 2D, 
the treatment with 4 µM Bafilomycin A1 confirmed that 
inhibition of autophagy significantly reduced the cytotoxic 
effect of Torin-2. These results indicated that autophagy is 
a critical determinant of the cytotoxic effects induced in 
B-pre ALL cells by Torin-2. 
Torin-2 causes pro-apoptotic effects on B-pre ALL 
cell lines 
To investigate whether the decreased viability 
was related to apoptosis, cells were treated for 24h with 
increasing concentrations of Torin-2 and analyzed by both 
Western blot and DNA staining. Cleavage of poly(ADP-
ribose)polymerase (PARP) in BV-173, SEM and NALM-
6 revealed the pro-apoptotic effect of Torin-2. REH and 
SUP-B15 cells were treated with Torin-2 at 0.5 µM for 
24h (Fig. 3A). DAPI staining revealed the morphological 
changes associated with apoptosis, such as chromatin 
condensation and nuclear fragmentation (Fig.3B). 
Apoptosis was further investigated by flow cytometric 
analysis of Annexin V-stained samples, that showed in 
NALM-6 and TOM-1 a significant and concentration-
dependent increase of apoptotic cells (Fig. 3C, left panel). 
To determine whether activated caspases are involved in 
the apoptotic action of Torin-2, we examined the effects 
Figure 1: Expression and phosphorylation status of mTOR and Akt and their downstream targets in B-pre ALL cell 
lines. Western blot analysis of B-pre ALL cell lines to detect the expression and phosphorylation levels of Akt, mTOR and its downstream 
substrates. Twenty-five µg of protein were blotted to each lane. Antibody to β-actin served as a loading control.
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of the broad spectrum caspase inhibitor Z-VAD-fmk on 
cell apoptosis as determined by annexin-V FITC binding. 
Torin-2-mediated apoptosis was blocked markedly by 25 
μM Z-VAD-fmk (Figure 3C, right panel). Therefore these 
results showed that Torin-2 induced caspase-dependent 
cell death.
Torin-2 affects the PI3K/Akt/mTOR pathway in 
B-pre ALL cells
To assess the effects of Torin-2 on the PI3K/Akt/
mTOR signaling pathway, we studied the expression and 
activation status of critical components of the PI3K/Akt/
mTOR cascade. NALM-6, RS4;11, SEM, TOM-1 and BV-
173 cells were treated with increasing concentrations of 
Torin-2 for 2h and Western blot was then performed (Fig. 
4). 
Torin-2 decreased the phosphorylation levels of 
mTOR on both the Ser 2448 and Ser 2481 residues. It 
should be remembered that the phosphorylation of mTOR 
on Ser 2481 is a mTORC2-selective autophosphorylation 
site [21]. mTORC1 inhibition had functional effects on 
two well known mTORC1 substrates, S6 and 4E-BP1. 
S6 was completely dephosphorylated on the Ser 235/236 
residue already at 50 nM concentration of Torin-2 in all 
cell lines, whereas 4E-BP1 was fully dephosphorylated on 
the Thr 37/46 site starting from the 100 nM concentration. 
Total levels of all these proteins were instead unaffected 
by Torin-2. 
mTORC2 inhibition had a readout in Ser 473 
Akt dephosphorylation and it was observable in all the 
cell lines starting from Torin-2 concentration of 50 nM. 
Despite some differences, also the Akt downstream 
substrate FoxO3A was dephosphorylated in a dose 
dependent fashion on its Thr 32 residue in all cell lines 
(Fig. 4).
Figure 2: Torin-2 is cytotoxic, cytostatic and induces autophagy in B-pre ALL cell lines. A. MTT assay of B-pre ALL cell 
lines treated with increasing concentrations of Torin-2 for 48h. One representative experiment is shown. B. Flow cytometric analysis for 
SEM and BV-173 cells treated with increasing concentrations of Torin-2 for 24h. Asterisks indicate statistically significant differences 
with respect to untreated cells (*p<0.05). Cell lines displayed are representative of the cell panel used in this study. C. Effect of Torin-2 
on autophagy  in BV-173, SEM and NALM-6 cells, documented by the lipidation of the autophagy marker LC3A/B. Antibody to β-actin 
served as a loading control. D. The activity of 3-MA in combination with Torin-2 is reported in the upper histogram, after SEM and BV-173 
treatment for 24h. Below, the effect on cell viability of SEM and BV-173 cells after treatment with Torin-2 and the autophagy inhibitor 
Bafilomycin A1 is reported. Results are the mean of three different experiments ± SD. Asterisks indicate statistically significant differences 
with respect to untreated cells (*p<0.05).
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Torin-2 prevents the reactivation of Akt upon 
mTOR inhibition in B-pre ALL cells
Since it has been previously described that in 
hematological malignancies [22, 23] and solid tumors [24, 
25] with constitutive PI3K/Akt activation, the rapamycin 
derivative inhibitor everolimus (RAD001) increased Akt 
phosphorylation, we sought to explore if Torin-2 might 
prevent Akt re-activation after mTORC1 inhibition.
For this set of experiments we decided to use the 
concentration of 0.15 μM, that represents nearly the 
average IC50 of Torin-2 in the panel of cell lines employed. 
We prolonged the treatment with Torin-2 up to 48h and 
we compared it with the mTORC1 inhibitor, RAD001, 
employed at the concentration of 0.6 μM. This value has 
been chosen to mirror a concentration of a mTORC1 
inhibitor (Temsirolimus) correspondent to the plasma 
concentration achievable in clinical trials [26]. As shown 
in Fig. 5A and B, in a range from 0.05 to 5 μM, RAD001 
alone could not achieve the IC50. Thus, RAD001 had a 
putative IC50 higher than 5 µM, whereas Torin-2 displayed 
an IC50 value < 0.2 μM in all cell lines. Interestingly, we 
found that either mTORC1 and mTORC2 substrates, 
including Akt, after 48h of Torin-2 treatment remained 
dephosphorylated (Fig. 5C). On the contrary, samples 
treated with RAD001 already after 24h showed a re-
phosphorylation of Akt. Direct (FoxO3A) or indirect (S6) 
downstream targets of Akt displayed the same behaviour 
(Fig. 5C).
The allosteric Akt inhibitor MK-2206 synergizes 
with RAD001 but not with Torin-2 
For therapeutic targeting of the PI3K/Akt/mTOR 
pathway, the combined inhibition at different points of the 
cascade often leads to more effective results than the use 
of a drug that acts on a single or dual targets [27]. To better 
assess the potential therapeutic value of Torin-2 in B-pre 
Figure 3: Torin-2 induces apoptosis. A. Western blot analysis documenting a Torin-2 concentration-dependent PARP cleavage in BV-
173, SEM and NALM-6 cells. Antibody to β-actin served as a loading control. B. DNA staining of REH and SUP-B15 with the fluorescent 
dye DAPI is reported. In REH and SUP-B15 treated with 0.5 µM Torin-2 various aspects of nuclear shrinkage, fragmentation and chromatin 
margination, that are associated with the apoptotic mode of cell death, are observable. C. On the left, flow cytometric analysis of NALM-6 
and TOM-1 cell lines treated with increasing concentrations of Torin-2. Samples were incubated with Annexin V-fluorescein isothiocyanate. 
On the right, MTT assay of NALM-6 and TOM-1 cells treated with Torin-2 and Z-VAD-fmk, a pan caspase inhibitor, is showed. Results are 
the mean of three different experiments ± SD.
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Figure 4: Torin-2 cytotoxicity is related to PI3K/Akt/mTOR signaling pathway inhibition. Western blot analysis for mTOR, 
Akt and their downstream targets S6, 4E-BP1 and FoxO3A in B-pre ALL cell lines. Twenty-five µg of protein were blotted to each lane. In 
all samples 2h of Torin-2 treatment with increasing concentrations was performed. β-actin served as a loading control. 
Figure 5: Torin-2 prevents Akt reactivation in B-pre ALL. A. MTT assay of B-pre ALL cell lines treated with increasing 
concentrations of RAD001 for 48h. One representative experiment of three is shown. B. IC50 values for Torin-2 and RAD001 on the 
viability of B-pre ALL cell lines after 48h. Results are the mean of three different experiments ± SD. C. Western blot analysis for PI3K/Akt/
mTOR signaling pathway in SEM, BV-173 and RS4;11 cells. Cells were treated with 0.15 μM Torin-2 and 0.6 μM RAD001 for different 
times of incubation. In RAD001 treated samples after 24h is evident the re-phosphorylation of Akt, FoxO3A and S6. β-actin served as a 
loading control.
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ALL, we analyzed its synergistic potential with MK-2206, 
an orally active, allosteric Akt inhibitor, which is currently 
tested in phase II clinical trials. We also compared this 
drug combination with a second one consisting of the 
association of MK-2206 and RAD001. The drugs were 
used at a fixed ratio (1:1 both for Torin-2/MK-2206 and 
RAD001/MK-2206).
After 48h of treatment, MTT assays were performed. 
The dual targeting of mTORC1/mTORC2 and Akt with 
Torin-2 and MK-2206 did not show a synergistic effect at 
any concentration, whereas the administration of RAD001 
and MK-2206 together resulted in a relevant synergistic 
cytotoxic effect in RS4;11 and BV-173 cell lines (Fig. 
6A). This phenomenon was more relevant in the range 
between 0.5 and 1 µM, as confirmed by the combination 
index (CI) values. Similar results were obtained with other 
B-pre ALL cell lines (supplementary Fig. 1). It should be 
noted that a comparison between the IC50 values obtained 
from the two different treatment at 48h (Torin-2/MK-2206 
and RAD001/MK-2206), showed that the IC50 values were 
very similar and comparable in each cell line (Fig. 6B).
We next studied the effects of the two drug 
combinations on the phosphorylation levels of Akt, 
FoxO3A and S6 protein. Torin-2 was used at 0.15 µM, 
RAD001 at 0.6 µM and MK-2206 at 0.5 µM for 30 
minutes and then Western blot analysis was performed. 
The concentration of MK-2206 was selected for 
either being in the range of maximal synergy and to 
be comparable to the plasma concentration that has 
been obtained in clinical trials in acute myelogenous 
leukemia [28]. Both SEM and SUP-B15 cell lines did 
not show a synergistic effect of Torin-2 and MK-2206 
on the phosphorylation levels of Akt, FoxO3A and S6. 
Interestingly, there was an additional downregulation of 
protein phosphorylation only when the dual treatment 
RAD001/MK-2206 was administered, thus confirming 
the synergistic effect in modulating the PI3K/Akt/mTOR 
pathway (Fig. 6C). To further assess these findings, we 
explored the effects of dual treatments on cell cycle, by 
flow cytometric analysis of PI-stained samples in RS4;11 
and BV-173 cells cultured for 24h. Both drug associations 
yielded comparable results. The treatment with Torin-2 
and MK-2206 was similar to the single administration 
of Torin-2 alone. At variance, the dual administration of 
Figure 6: Dual administration of Torin-2 or RAD001 with MK-2206 in B-pre ALL cell lines. A: B-pre ALL cell lines were 
treated for 48h with Torin-2 or RAD001, either alone or in combination with MK-2206. Results are the mean of three different experiments 
± SD. Combination index (CI) value for each data point was calculated with the appropriate software for dose effect analysis (Calcusyn). 
B: IC50 values for Torin-2 or RAD001 in combination with MK-2206 on the viability of B-pre ALL cell lines at 48h. Results are the mean 
of three different experiments ± SD. C: Western blot analysis for PI3K/Akt/mTOR in SEM and SUP-B15 cells. Cells were treated for 30 
minutes with 0.15 μM Torin-2 or 0.6 μM RAD001 in combination with 0.5 μM MK-2206. β-actin served as a loading control. 
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RAD001 and MK-2206 increased the percentage of cells 
in the G0/G1 phase of the cell cycle in comparison with 
single drug administration (Fig. 7A).
We also examined the pro-apoptotic effect of the 
two drug association on NALM-6 and TOM-1 cells. Cells 
were treated with 0.15 µM Torin-2 or 0.6 µM RAD001 
and 0.5 µM MK-2206 for 24h and then analyzed by 
MTT assays. Using these drug concentrations, nearly 
20% of apoptotic cells were observed in either cell 
line with both drug combinations. However, apoptosis 
induced by the treatment with Torin-2 and MK-2206 was 
comparable with that observable with the administration 
of Torin-2 alone, whereas the apoptosis obtained with the 
dual administration of RAD001 and MK-2206 was the 
consequence of a synergistic effect (Fig. 7B).
Finally, the effect of Bafilomycin A1 on dual 
targeting the PI3K/Akt/mTOR pathway with a 
combination of Torin-2/MK-2206 or RAD001/MK-
2206 was analyzed. A consistent inhibition of autophagy 
increased the viability of B-pre ALL cells treated with 
Torin-2/MK-2206 (Fig. 7C, left panel) and to a lower 
extent with RAD001/MK-2206 (Fig. 7C, right panel). This 
difference may rely on the different mechanism through 
which autophagy is recruited by the drugs: those who act 
on mTOR, activated autophagy as a cell death mechanism 
[16],whereas the drug that inhibit Akt, induced autophagy 
as a cell protection mechanism [29].
Torin-2 suppresses doxorubicin-induced cell cycle 
checkpoint activation 
When DNA is damaged by DNA intercalating 
agents, such as Doxorubicin, double stranded breaks 
Figure 7: Effects of dual administration of Torin-2 or RAD001 with MK-2206 in B-pre ALL cell lines. A: Flow cytometric 
representation of the effects of Torin-2/MK-2206 and RAD001/MK-2206 combinations on the cell cycle of RS4;11 and BV-173 cell lines 
after 24h of treatment. Results are the mean of three different experiments ± SD. B: Flow cytometric analysis of NALM-6 and TOM-1 
cell lines treated with increasing concentrations of Torin-2 or RAD001, alone and in combination with MK-2206, for 24h. Samples were 
incubated with Annexin V-fluorescein isothiocyanate and then analyzed for apoptosis. Results are the mean of three different experiments 
± SD. Asterisks indicate statistically significant differences with respect to untreated cells (*p<0.05). C. MTT assay representation of 
the autophagy effects on NALM-6 and TOM-1 cells treated with Torin-2/MK-2206 or RAD001/MK-2206 combinations or plus the 
administration of the autophagy inhibitor Bafilomycin A1. Results are the mean of three different experiments ± SD. Asterisks indicate 
statistically significant differences with respect to untreated cells (*p<0.05).
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(DSBs) trigger recruitment of ATM and ATR to the 
damage site which in turn phosphorylates histone H2AX 
leading to foci formation [30].
Torin-2 also exhibited potent biochemical and 
cellular activity against PIKK family kinases including 
ATM, ATR, and DNA-PK, whose inhibition sensitized 
cells to irradiation [15]. The ATR pathway is known to 
transmit DNA damage signals through the ATR-CHK1 
kinase cascade and activation of cell cycle checkpoint 
regulators such as CHK1 and CHK2 has a critical role in 
promoting cell cycle arrest in response to cytotoxic agents, 
including doxorubicin [31]. 
We tested if the combination of Doxorubicin and 
Torin-2 may exert additional cytotoxic activity than 
the two drugs administered alone. In Figure 8A are 
shown the results of MTT assays of two representative 
cell lines (SEM and TOM-1) analyzed for cell viability 
after treatment with the drugs used either as single 
agents or combined together. In both cell lines, the drug 
combination induced a stronger decrease in cell viability 
(Fig. 8A). Doxorubicin alone induced phosphorylation of 
CHK1 (Ser 345, a marker for ATR activity) and CHK2 
(Thr 68, a readout for ATM activity). In contrast, Torin-2 
(0.25 µM) alone did not increase CHK1 and CHK2 
phosphorylation, whereas it dramatically decreased the 
phosphorylation induced by Doxorubicin (Fig. 8B). One 
prominent chromatin modification in response to DNA 
damage is phosphorylation of histone H2AX on Ser 139, 
which is referred to as γ-H2AX [32]. 
Torin-2 inhibited the DNA damage response induced 
by Doxorubicin, as documented by the effects on the 
levels of phosphorylated γ-H2AX on the Ser 139 residue 
(Fig. 8B).
DISCUSSION
Owing to the fundamental role of PI3K/Akt/mTOR 
pathway in tumor development and progression, there 
has been a significant interest in developing inhibitors 
against components of this pathway, up to having now 
many compounds currently under evaluation in clinical 
trials. ATP-competitive mTOR kinase inhibitors represent 
a promising new approach to target the PI3K/Akt/mTOR 
pathway with potentially greater tolerability than dual 
PI3K/mTOR inhibitors [5, 33, 34]. It has been previously 
reported that first generation mTOR kinase inhibitors had 
improved efficacy compared to rapamycin in models of 
Figure 8: Torin2 suppresses Doxorubicin-induced cell cycle checkpoint activation. A:  MTT assay showing the cytotoxic 
effect of Torin-2 and Doxorubicin (0.015 µM) alone or in combination in SEM and TOM-1 cells. DOXO, Doxorubicin-treated cells. 
Results are the mean of three different experiments ± SD. Asterisks indicate statistically significant differences with respect to untreated 
cells (*p<0.05). B: Western blot analysis of SEM cells showing the activation by Doxorubicin treatment of cell cycle checkpoint regulators 
Chk1 and Chk2, markers for ATR or ATM activity, respectively. Torin-2 alone did not modify CHK1 and CHK2 phosphorylation, whereas 
it dramatically decreased after Doxorubicin administration. Torin-2 also influenced the levels of phosphorylated γ-H2AX, inhibiting its 
phosphorylation after Doxorubicin treatment. β-actin served as a loading control.
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Ph+ B-ALL [35]. 
We have recently explored the therapeutic potential 
of RAD001, an allosteric mTORC1 inhibitor in pre-
clinical models of B-pre ALL [16]. We documented that 
RAD001 decreased cell viability, induced cell cycle arrest 
in G0/G1 phase and caused apoptosis in B-pre ALL cell 
lines. Autophagy was also induced, which was important 
for the RAD001 cytotoxic effect, as downregulation of 
Beclin-1 reduced drug cytotoxicity. RAD001, used in 
the micromolar range and administered 24h before MK-
2206 showed the capacity to synergize with MK-2206 
in both cell lines and patient samples [16]. In this study, 
we evaluated for the first time the efficacy of the novel 
mTORC1/mTORC2 second generation, ATP-competitive 
inhibitor, Torin-2 [14] in pre-clinical settings of Ph+ and 
Ph- B-pre ALL.
Torin-2 was both cytotoxic and cytostatic in a 
nanomolar range to B-pre ALL cell lines in a concentration 
dependent mechanism, as demonstrated by MTT assays, 
flow cytometric analysis of Annexin V-stained samples 
and of PI-stained samples. Apoptosis resulted to play 
a determinat role in the killing mechanism, since the 
treatment with a pan caspase inhibitor protected the 
cells from Torin-2 cytotoxic effect. These results are in 
agreement with those observed with other drugs in acute 
myeloid leukemia [36, 37].
Torin-2 also induced autophagy, as documented 
by increased expression of the lipidated form of LC3. 
In order to demonstrate whether autophagy was either 
a survival or a death mechanism, B-pre ALL were co-
treated with the autophagic sequestration inhibitors, 3-MA 
and Bafilomycin A1. We found that either treatment with 
3-MA and Bafilomycin A1, resulted in a lower sensitivity 
of both SEM and BV-173 cells to the cytotoxic effects of 
RAD001 and indicated that Torin-2-induced autophagy 
was very important for the cytotoxic effects of the drug. 
The phosphorylation status of the key elements of the 
PI3K/Akt/mTOR pathway, assessed by Western blot, 
was equally sensitive to Torin-2 inhibition in either cells 
harboring or not the Bcr-Abl fusion protein. 
RAD001, when used in the nanomolar range 
against this panel of cell lines, was much less cytotoxic 
than Torin-2, as it displayed IC50s > 5 µM. This superior 
efficacy of the second generation inhibitors, has been 
also reported for MLN0128, another mTORC1/mTORC2 
inhibitor, which displayed an improved anti-leukemic 
activity when compared to first generation inhibitors, 
in Ph- B-ALL derived from both adult and pediatric 
subjects [21]. It has been reported that in solid tumor 
models, activation of mTORC1 drives p70S6K-mediated 
degradation of the IR/IGF-1R adaptor protein IRS-1, and 
is therefore a negative regulator of PI3K [38]. Accordingly, 
drugs targeting mTORC1 block this feedback and trigger 
reactivation of the pathway and re-phosphorylation of 
Akt on Ser 473 residue in acute myelogenous leukemia 
cells [22, 39]. The issue of Akt reactivation in response to 
mTORC1 inhibition, has not been throughly investigated 
in B-pre ALL. It is worth highlighting that Torin-2 
maintained a prolonged suppression of mTORC1/
mTORC2 with a sustained anti-proliferative effect, 
overcoming the limitations of rapalogs such as RAD001, 
as demonstrated by our findings, which resulted in re/
hyper-phosphorylation of Akt and could hamper their 
anti-tumor action and enhance resistance to antineoplastic 
therapy, thus resulting in a poor outcome [40]. 
Akt activity is directly downregulated on Thr 308 
by the protein phosphatase PP2A [41], which is also 
critically involved in regulation of cell cycle progression 
[42] and DNA damage response [43]. Accumulating 
evidence indicates that PP2A acts as a tumor suppressor 
and impairment of PP2A activity may result in loss of this 
function [7]. The capacity of Torin-2, but not of RAD001, 
to inhibit both mTORC1 and 2 may represent a possible 
mechanism for why Akt is not re-phosphorylated with this 
drug on the Ser 473 residue and this phosphorylation may 
be independent form PP2A activity. 
The Torin-2 prolonged suppression of Akt 
phosphorylation may overcome the occurrence of PP2A 
oncosuppressor altered function and may render Akt 
inhibition independent from the activity of PP2A, thus 
proposing this therapeutic options as a potential tool that 
could act functionally on either impaired Akt and PP2A 
functions. 
Overall, Torin-2 alone was as potent as a 
combination consisting of RAD001 and MK-2206, in 
terms of reduction of cell viability, apoptosis induction, 
and cell cycle block. In contrast, when MK-2206 was 
combined with Torin-2, it did not display any synergistic 
effect. Interestingly, the presence of synergism or its lack 
was evident also when the phosphorylation status of key 
elements of the pathway was analyzed by Western blot. 
Both ATM and ATR play a central role in 
coordinating the DNA damage response, including 
cell cycle checkpoint control and apoptosis [44]. Since 
the results by Liu et al. [15], using purified enzymes, 
suggested that Torin-2 was also an inhibitor of several 
PIKK family members including ATR, ATM, and DNA-
PK, we investigated if this was also true in B-pre ALL 
cell lines. Western blot analysis documented that indeed 
Torin-2 inhibited ATM and ATR in intact cells and, by 
inhibiting DNA repair, potentiated the cytotoxic effect of 
Doxorubicin. Torin-2 displayed an obvious advantage over 
RAD001, which also induced a similar phenomenon, as 
Torin-2 could be used in the nanomolar range, whereas 
RAD001 required a concentration as high as 16 µM [45], 
which could not be attained in vivo. In addition, very 
recently it has been reported that Akt inhibition with 
CCT12893 increased the phosphorylation of CHK1/CHK2 
and γ-H2AX [46]. 
These findings open a new very interesting field to 
be further explored in the future regarding the therapeutic 
effect of PI3K/Akt/mTOR inhibitors involving DNA 
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damage sensors and cell cycle checkpoints such as CHK1 
and CHK2. 
In conclusion, our data indicate that the novel 
mTORC1/mTORC2 kinase inhibitor Torin-2 can 
suppress the growth of both Ph+ and Ph- B-pre ALL 
cells and extend the finding that the antiproliferative 
and proapoptotic effects of PI3K/Akt/mTOR pathway 
inhibitors are independent from ABL-translocation, as 
reported in long-term cultures of Ph+ and Ph- B-precursor 
ALL cells from patients [40]. Remarkably, Torin-2, 
even after a 48h incubation, blocked the reactivation of 
Akt, thus confirming the new therapeutic hopes that this 
second generation of inhibitors is developing. In addition, 
Torin-2 could be also effective in combination with 
chemotherapeutic DNA-damaging agents, in light of its 
capacity of blocking DNA repair.
Interestingly, with the aim of improving B-pre 
ALL treatment, we also came to the conclusion that low 
concentrations of RAD001 and MK-2206 (which can 
be attained in vivo) may achieve a therapeutic efficacy 
comparable to an mTORC1/mTORC2 inhibitor. These 
therapeutic strategies could be particularly effective when 
combined with targeted next generation sequencing of 
tumor samples, since genomic alterations can be detected 
and help to identify refractory patients with aberrations 
putatively activating the PI3K/Akt/mTOR pathway [47, 
48]. These pharmacological options targeting PI3K/Akt/
mTOR at different points of the signaling pathway cascade 
or in combination with conventional chemotherapy might 
represent a new therapeutic potential for treatment of 
B-pre ALL patients.
MATERIALS AND METHODS 
Materials 
Alpha-MEM, McCoy’s 5A and RPMI-1640 
mediums, fetal bovin serum (FBS), penicillin and 
streptomycin were from Lonza (Lonza Milano SRL, 
Milan, Italy). Torin-2, RAD001, and MK-2206 were 
from Selleck Chemicals (Houston, TX, USA). For cell 
viability determination, Cell Proliferation Kit I (MTT) 
was purchased from Roche Applied Science (Basel, 
Switzerland). Annexin V/7-AAD detection kit was 
from Merck-Millipore (Darmstadt, Germany). Akt-1, 
Ser 473 p-Akt-1, and FoxO3A primary antibodies were 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
while all the other antibodies were from Cell Signaling 
Technology (Danvers, MA, USA), including the rabbit 
secondary antibody. The mouse secondary antibody, 
Bafilomycin A1, Z-VAD-fmk, 3-Methyladenine (3-
MA), 1,4-Diazabicyclo[2.2.2]octane (DABCO) and 4′, 
6 diamidino-2-pheny-lindole (DAPI) were from Sigma 
Aldrich (Milan, Italy). Signals were detected with the ECL 
Plus reagent purchased from Perkin Elmer (Boston, MA, 
USA).
Cell culture and Western blot analysis
All the B-pre acute lymphoblastic leukemia cell 
lines were obtained from Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (Braunschweig, 
Germany). SEM, REH, BV-173 and NALM6 were grown 
in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS); RS4;11 cells were 
grown in Alpha-MEM medium with 10% FBS; TOM-1 
cells were grown in RPMI 1640 medium with 20% FBS 
and SUP-B15 cells were grown in McCoy’s 5A medium 
with 20% FBS. All the media were supplemented with 
100 units/ml penicillin and 100 mg/ml streptomycin. The 
cells were grown at a density of 0.5 to 2 x 106 cells/ml 
and were incubated at 37°C with 5% CO2. Western blot 
analysis was performed by standard methods as described 
elsewhere [49].
Cell viability analysis 
MTT (3-(4,5-dimethylthythiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assays were performed as 
previously described [50]. 
Cell cycle analysis
Cell cycle analysis was performed using the MuseTM 
Cell Analyzer (Merck Millipore, Milan, Italy) and/or 
propidium iodide (PI)/RNase A staining by flow cytometry 
according to standard techniques, as described elsewhere 
[51]. In brief, after 24h of drug treatment, cells were 
harvested, centrifuged at 300 x g for 5 min and washed 
once with 1X PBS. After fixing them with 70% ethanol 
at 20°C, cells were centrifuged at 300 x g for 5 min and 
washed once with 1X PBS. Then 200 μl of MuseTM Cell 
Cycle reagent or 100 μl of propidium iodide (PI)/RNase A 
staining was added to each tube with an incubation of 30 
min at room temperature in the dark. Samples were then 
analyzed according to the manufacturer’s instructions.
PI/Annexin V assay
Apoptosis analysis was performed by staining with 
Annexin V/7-AAD, using the MuseTM Cell Analyzer in 
according to the manufacturer’s instructions. In brief, a 
100 μl treated cell suspension was labeled for 20 min in 
the dark with the same volume of the MuseTM Annexin-V 
& Dead Cell reagent (Merck Millipore). Subsequently, 
quantitative detection of Annexin-V/7-AAD positive cells 
was performed with the MuseTM Cell Analyzer [51].
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DAPI staining
Cell nuclear morphology was evaluated by 
fluorescence microscopy following DAPI staining. 
Cells were treated with Torin-2 for 24 h. The cells were 
washed with PBS (pH 7.4), cytocentrifuged, fixed with 
4% paraformaldehyde/PBS and stained for 3 min with 
1 μg/mL DAPI. The cells were then washed with PBS, 
specimens were embedded in glycerol with antifading 
agent (DABCO) and examined under Zeiss Axiophot 
fluorescence microscope (Zeiss, Germany).
Combined drug effect analysis
The combination effect and the potential synergy 
of Torin-2 and RAD001 with MK-2206 were evaluated 
from quantitative analysis of dose–effect relationship, 
as described previously [16]. For each Torin-2/MK-
2206 or RAD001/MK-2206 combination experiment, a 
combination index (CI) number was calculated using the 
Biosoft CalcuSyn software (Biosoft, Cambridge, UK). 
This method of analysis generally defines CI values from 
0.9 to 1.1 as additive, from 0.3 to 0.9 as synergistic and 
0.3 as strongly synergistic, whereas values over 1.1 are 
considered as antagonistic.
Statistical evaluation
The data are presented as mean values from three 
separate experiments ± s.d. Data were statistically 
analyzed by a Dunnet test after one-way analysis of 
variance (ANOVA) at a level of significance of P<0.05 vs 
control samples.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by a MIUR FIRB 2010 
grant to SC (RBAP10Z7FS_002), MIUR FIRB 2010 grant 
to AMM (RBAP10447J_003), by a MIUR PRIN-2009 
grant to SC and by current research funds IRCCS Burlo 
Garofolo to GZ.
REFERENCES
1. Lovejoy CA and Cortez D. Common mechanisms of PIKK 
regulation. DNA repair. 2009; 8(9):1004-1008.
2. Abraham RT. PI 3-kinase related kinases: ‘big’ players in 
stress-induced signaling pathways. DNA repair. 2004; 3(8-
9):883-887.
3. Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D 
and Tamburini J. LKB1/AMPK/mTOR signaling pathway 
in hematological malignancies: from metabolism to cancer 
cell biology. Cell Cycle. 2011; 10(13):2115-2120.
4. Francipane MG and Lagasse E. mTOR pathway in 
colorectal cancer: an update. Oncotarget. 2014; 5(1):49-66.
5. Janes MR and Fruman DA. Targeting TOR dependence in 
cancer. Oncotarget. 2010; 1(1):69-76.
6. Eyre TA, Collins GP, Goldstone AH and Cwynarski K. 
Time now to TORC the TORC? New developments in 
mTOR pathway inhibition in lymphoid malignancies. 
British journal of haematology. 2014; 166(3):336-351.
7. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, 
Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte 
G, Mazzarino MC, Candido S, Libra M, Basecke J, 
Mijatovic S, Maksimovic-Ivanic D, Milella M, et al. 
Mutations and deregulation of Ras/Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR cascades which alter therapy 
response. Oncotarget. 2012; 3(9):954-987.
8. Pui CH and Evans WE. A 50-year journey to cure childhood 
acute lymphoblastic leukemia. Seminars in hematology. 
2013; 50(3):185-196.
9. Inaba H, Greaves M and Mullighan CG. Acute 
lymphoblastic leukaemia. Lancet. 2013; 381(9881):1943-
1955.
10. Pui CH, Mullighan CG, Evans WE and Relling MV. 
Pediatric acute lymphoblastic leukemia: where are we going 
and how do we get there? Blood. 2012; 120(6):1165-1174.
11. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg 
ME, Sather HN, Hunger SP and Devidas M. Long-term 
results of the children’s cancer group studies for childhood 
acute lymphoblastic leukemia 1983-2002: a Children’s 
Oncology Group Report. Leukemia. 2010; 24(2):285-297.
12. Tasian SK, Teachey DT and Rheingold SR. Targeting 
the PI3K/mTOR Pathway in Pediatric Hematologic 
Malignancies. Frontiers in oncology. 2014; 4:108.
13. Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, 
Carroll WL, Winick NJ, Hunger SP, Gaynon PS and Loh 
ML. Factors influencing survival after relapse from acute 
lymphoblastic leukemia: a Children’s Oncology Group 
study. Leukemia. 2008; 22(12):2142-2150.
14. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, 
Sabatini DM and Gray NS. Discovery of 9-(6-aminopyridin-
3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]
naphthyridin-2( 1H)-one (Torin2) as a potent, selective, and 
orally available mammalian target of rapamycin (mTOR) 
inhibitor for treatment of cancer. Journal of medicinal 
chemistry. 2011; 54(5):1473-1480.
15. Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, 
Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan 
D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang 
Y, et al. Characterization of Torin2, an ATP-competitive 
inhibitor of mTOR, ATM, and ATR. Cancer research. 2013; 
73(8):2574-2586.
Oncotarget10046www.impactjournals.com/oncotarget
16. Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, 
Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey JA 
and Capitani S. Targeting the PI3K/Akt/mTOR signaling 
pathway in B-precursor acute lymphoblastic leukemia and 
its therapeutic potential. Leukemia. 2014; 28(4):739-748.
17. Rubinsztein DC, Codogno P and Levine B. Autophagy 
modulation as a potential therapeutic target for diverse 
diseases. Nature reviews Drug discovery. 2012; 11(9):709-
730.
18. Gewirtz DA. The four faces of autophagy: implications for 
cancer therapy. Cancer research. 2014; 74(3):647-651.
19. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, 
Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, 
Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed 
O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, et 
al. Guidelines for the use and interpretation of assays for 
monitoring autophagy. Autophagy. 2012; 8(4):445-544.
20. Shacka JJ, Klocke BJ and Roth KA. Autophagy, 
bafilomycin and cell death: the “a-B-cs” of plecomacrolide-
induced neuroprotection. Autophagy. 2006; 2(3):228-230.
21. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, 
Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, 
Rommel C and Fruman DA. Efficacy of the investigational 
mTOR kinase inhibitor MLN0128/INK128 in models of 
B-cell acute lymphoblastic leukemia. Leukemia. 2013; 
27(3):586-594.
22. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, 
Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C 
and Bouscary D. Mammalian target of rapamycin (mTOR) 
inhibition activates phosphatidylinositol 3-kinase/Akt by 
up-regulating insulin-like growth factor-1 receptor signaling 
in acute myeloid leukemia: rationale for therapeutic 
inhibition of both pathways. Blood. 2008; 111(1):379-382.
23. Advani AS, Mahfouz RZ, Maciejewski J, Rybicki 
L, Sekeres M, Tripp B, Kalaycio M, Bates J and 
Saunthararajah Y. Ribosomal S6 kinase and AKT 
phosphorylation as pharmacodynamic biomarkers in 
patients with myelodysplastic syndrome treated with 
RAD001. Clinical lymphoma, myeloma & leukemia. 2014; 
14(2):172-177 e171.
24. Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP 
and Feron O. PTEN deficiency is associated with reduced 
sensitivity to mTOR inhibitor in human bladder cancer 
through the unhampered feedback loop driving PI3K/Akt 
activation. British journal of cancer. 2013; 109(6):1586-
1592.
25. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, 
Barys L, Maira SM, Kwiatkowski D and Lane HA. 
Increased AKT S473 phosphorylation after mTORC1 
inhibition is rictor dependent and does not predict tumor 
cell response to PI3K/mTOR inhibition. Molecular cancer 
therapeutics. 2009; 8(4):742-753.
26. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher 
JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, 
Dukart G and Sherman ML. Randomized phase II study 
of multiple dose levels of CCI-779, a novel mammalian 
target of rapamycin kinase inhibitor, in patients with 
advanced refractory renal cell carcinoma. Journal of clinical 
oncology. 2004; 22(5):909-918.
27. Dienstmann R, Rodon J, Serra V and Tabernero J. Picking 
the point of inhibition: a comparative review of PI3K/AKT/
mTOR pathway inhibitors. Molecular cancer therapeutics. 
2014; 13(5):1021-1031.
28. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng 
Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, 
Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly 
KA, et al. Preclinical and early clinical evaluation of the 
oral AKT inhibitor, MK-2206, for the treatment of acute 
myelogenous leukemia. Clinical cancer research. 2014; 
20(8):2226-2235.
29. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, 
Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda 
F, Pagliaro P, Pession A, McCubrey JA, Capitani S and 
Martelli AM. Cytotoxic activity of the novel Akt inhibitor, 
MK-2206, in T-cell acute lymphoblastic leukemia. 
Leukemia. 2012; 26(11):2336-2342.
30. Reinhardt HC and Yaffe MB. Kinases that control the cell 
cycle in response to DNA damage: Chk1, Chk2, and MK2. 
Current opinion in cell biology. 2009; 21(2):245-255.
31. Wang X, Zeng L, Wang J, Chau JF, Lai KP, Jia D, 
Poonepalli A, Hande MP, Liu H, He G, He L and Li B. A 
positive role for c-Abl in Atm and Atr activation in DNA 
damage response. Cell death and differentiation. 2011; 
18(1):5-15.
32. Neumann J, Boerries M, Kohler R, Giaisi M, Krammer 
PH, Busch H and Li-Weber M. The natural anticancer 
compound rocaglamide selectively inhibits the G1-S-phase 
transition in cancer cells through the ATM/ATR-mediated 
Chk1/2 cell cycle checkpoints. International journal of 
cancer. 2014; 134(8):1991-2002.
33. Vilar E, Perez-Garcia J and Tabernero J. Pushing the 
envelope in the mTOR pathway: the second generation of 
inhibitors. Molecular cancer therapeutics. 2011; 10(3):395-
403.
34. Wander SA, Hennessy BT and Slingerland JM. Next-
generation mTOR inhibitors in clinical oncology: how 
pathway complexity informs therapeutic strategy. The 
Journal of clinical investigation. 2011; 121(4):1231-1241.
35. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, 
Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin 
MB, Ren P, Liu Y, Rommel C and Fruman DA. Effective 
and selective targeting of leukemia cells using a TORC1/2 
kinase inhibitor. Nature medicine. 2010; 16(2):205-213.
36. Piedfer M, Dauzonne D, Tang R, N’Guyen J, Billard C 
and Bauvois B. Aminopeptidase-N/CD13 is a potential 
proapoptotic target in human myeloid tumor cells. FASEB 
journal. 2011; 25(8):2831-2842.
37. Merhi F, Tang R, Piedfer M, Mathieu J, Bombarda I, Zaher 
M, Kolb JP, Billard C and Bauvois B. Hyperforin inhibits 
Oncotarget10047www.impactjournals.com/oncotarget
Akt1 kinase activity and promotes caspase-mediated 
apoptosis involving Bad and Noxa activation in human 
myeloid tumor cells. PLOS ONE. 2011; 6(10):e25963.
38. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, 
Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard 
S and Rosen N. mTOR kinase inhibition causes feedback-
dependent biphasic regulation of AKT signaling. Cancer 
discovery. 2011; 1(3):248-259.
39. Bertacchini J, Guida M, Accordi B, Mediani L, Martelli 
AM, Barozzi P, Petricoin E, 3rd, Liotta L, Milani G, 
Giordan M, Luppi M, Forghieri F, De Pol A, Cocco 
L, Basso G and Marmiroli S. Feedbacks and adaptive 
capabilities of the PI3K/Akt/mTOR axis in acute myeloid 
leukemia revealed by pathway selective inhibition and 
phosphoproteome analysis. Leukemia. 2014: doi: 10.1038/
leu.2014.123. [Epub ahead of print].
40. Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, 
Liebermann M, Falkenburg JH, Ruthardt M and Ottmann 
OG. Differential effects of selective inhibitors targeting 
the PI3K/AKT/mTOR pathway in acute lymphoblastic 
leukemia. PLOS ONE. 2013; 8(11):e80070.
41. Eichhorn PJ, Creyghton MP and Bernards R. Protein 
phosphatase 2A regulatory subunits and cancer. Biochimica 
et biophysica acta. 2009; 1795(1):1-15.
42. Nolt JK, Rice LM, Gallo-Ebert C, Bisher ME and Nickels 
JT. PP2A (Cdc)(5)(5) is required for multiple events during 
meiosis I. Cell Cycle. 2011; 10(9):1420-1434.
43. Lee HJ, Hwang HI and Jang YJ. Mitotic DNA damage 
response: Polo-like kinase-1 is dephosphorylated through 
ATM-Chk1 pathway. Cell Cycle. 2010; 9(12):2389-2398.
44. Shiloh Y and Ziv Y. The ATM protein kinase: regulating 
the cellular response to genotoxic stress, and more. Nature 
reviews Molecular cell biology. 2013; 14(4):197-210.
45. Saunders PO, Weiss J, Welschinger R, Baraz R, Bradstock 
KF and Bendall LJ. RAD001 (everolimus) induces dose-
dependent changes to cell cycle regulation and modifies 
the cell cycle response to vincristine. Oncogene. 2013; 
32(40):4789-4797.
46. Wang FZ, Chang ZY, Fei HR, Yang MF, Yang XY and Sun 
BL. CCT128930 induces cell cycle arrest, DNA damage, 
and autophagy independent of Akt inhibition. Biochimie. 
2014; 103:118-125.
47. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA and 
Kurzrock R. Identification of novel therapeutic targets in 
the PI3K/AKT/mTOR pathway in hepatocellular carcinoma 
using targeted next generation sequencing. Oncotarget. 
2014; 5(10):3012-3022.
48. Woo JS, Alberti MO and Tirado CA. Childhood B-acute 
lymphoblastic leukemia: a genetic update. Experimental 
hematology & oncology. 2014; 3:16.
49. Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, 
Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, 
Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey 
JA and Martelli AM. A combination of temsirolimus, 
an allosteric mTOR inhibitor, with clofarabine as a new 
therapeutic option for patients with acute myeloid leukemia. 
Oncotarget. 2012; 3(12):1615-1628.
50. Buontempo F, Chiarini F, Bressanin D, Tabellini G, 
Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA 
and Martelli AM. Activity of the selective IkappaB kinase 
inhibitor BMS-345541 against T-cell acute lymphoblastic 
leukemia: involvement of FOXO3a. Cell Cycle. 2012; 
11(13):2467-2475.
51. Simioni C, Martelli AM, Cani A, Cetin-Atalay R, 
McCubrey JA, Capitani S and Neri LM. The AKT inhibitor 
MK-2206 is cytotoxic in hepatocarcinoma cells displaying 
hyperphosphorylated AKT-1 and synergizes with 
conventional chemotherapy. Oncotarget. 2013; 4(9):1496-
1506.
